ARTICLE | Clinical News
BGB324: Phase Ia data
April 21, 2014 7:00 AM UTC
An open-label Phase Ia trial in 32 healthy volunteers showed that single doses of up to 1.5 g oral BGB324 were well tolerated. Data were presented at the American Association for Cancer Research meeti...